Tax Dodger Apple Te...
Health Care: Drugs
Amarin Corporation PLC (AMRN: NASDAQ)
$6.98 -0.07 | -0.99%
05/21/13 - 04:00 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| AMRN | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -18.21 | -32.47 | 221.62 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | |
| Net Income | 2.02 | 0.00 | |
| EPS | -0.11 | 0.00 |
Earnings for AMRN:
| EBITDA | -116.00 |
| REVENUE | 0.00 |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.38 | $-0.31 | $-1.44 | $-0.80 |
| Number of Analysts | 5 | 5 | 4 | 4 |
| High Estimate | $-0.26 | $-0.08 | $-1.13 | $0.36 |
| Low Estimate | $-0.42 | $-0.49 | $-1.87 | $-1.52 |
| Prior Year | $-0.24 | $-0.29 | $-0.99 | $-1.44 |
| Growth Rate (Year over Year) | -56.67% | -7.59% | -45.45% | 44.79% |
Portfolios with AMRN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Useralexr685
- ContributorDrugs Facing FDA Approval i...
- ContributorHigh Volume Technicals for ...
- ContributorBreakout Stocks Of The Week...
- UserHassan Portfolio
- Contributor4 Drug Stocks Facing FDA Ap...
- UserLividog
- ContributorStocks Rising On Unusual Vo...
- UserPharma
Latest AMRN Headlines from TheStreet
- Amarin Announces Approval Of Supplemental New Drug Application For Chemport As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier 04.18.13 | 06:04 am
- Amarin Announces New Clinical Data Showing Significant Reductions In Apolipoprotein C-III Levels In MARINE And ANCHOR Studies Of Vascepa(R) 04.08.13 | 06:04 am
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 3 Volatile Drug Stocks To Watch 04.01.13 | 03:04 pm
- Steve Rosenman Says Amarin Has Sticky Web Eyeballs! 03.27.13 | 04:03 pm
- Amarin's Sloooow Vascepa Launch 03.25.13 | 01:03 pm
- 'Mad Money' Lightning Round: Realogy Is Great, Cisco Terrific 03.22.13 | 06:03 am
- Cramer's 'Mad Money' Recap: It's Time to Pause 03.21.13 | 08:03 pm
- Keryx CEO vs. A Short Seller: Zerenex Patent Debate 03.13.13 | 07:03 am
Press Releases for AMRN
- Amarin To Present At The Deutsche Bank 26th Annual Healthcare Conference - PR Newswire 04.26.11 | 08:04 am
- Amarin's AMR101 Phase 3 ANCHOR Trial Meets All Primary And Secondary Endpoints With Statistically Significant Reductions In Triglycerides At Both 4 Gram And 2 Gram Doses And Statistically Significant Decrease In LDL-C - PR Newswire 04.18.11 | 02:04 am
- Phase 3 MARINE Trial Data To Be Presented In May At The National Lipid Association 2011 Annual Scientific Sessions - PR Newswire 04.05.11 | 08:04 am
- Amarin To Present At The 10th Annual Needham Healthcare Conference - PR Newswire 03.31.11 | 07:03 am
Partner Headlines for AMRN
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.08.13 | 01:04 pm
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- 4 Healthcare Stock Stories for Monday Investment Wellness - Wall St. Cheat Sheet 04.01.13 | 02:04 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Stock Watch Tuesday, 8 January - Seeking Alpha 01.08.13 | 09:01 am
- Stock Watch Wednesday, 2 January - Seeking Alpha 01.02.13 | 08:01 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Pre-Market Most Active for Dec 7, 2012 : BAC, QQQ, NOK, AMRN, VNTV, AVGO, MEMP, AAPL, FB, SAN, C, FCX - NASDAQ 12.07.12 | 01:12 pm
- After Hours Most Active for Dec 6, 2012 : MMR, BX, QQQ, S, AMRN, EPHC, BAC, EMC, AIG, DISH, LINTA, ORCL - NASDAQ 12.06.12 | 09:12 pm
